A Study of BMS-863233 in Patients With Advanced and/or Metastatic Solid Tumors
| Status: | Terminated |
|---|---|
| Conditions: | Cancer, Cancer, Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/21/2016 |
| Start Date: | May 2009 |
| End Date: | August 2010 |
A Phase 1/2 Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BMS-863233 in Subjects With Advanced and/or Metastatic Solid Tumors
The purpose of this study is to determine safety, tolerability and maximum tolerated dose of
BMS-863233 in subjects advanced and/or Metastatic solid tumors.
BMS-863233 in subjects advanced and/or Metastatic solid tumors.
Phase 1 Inclusion Criteria:
- Subjects with advanced and/or metastatic solid tumors who are either refractory to or
have relapsed from standard therapies, or for whom a standard therapy does not exist.
- ECOG performance status ≤ 2
- Accessible for treatment, PK sample collection and required study follow-up
- Total Bilirubin ≤ 1.5 x ULN and ALT, AST ≤ 2.5 x ULN
Exclusion Criteria:
- Women who are pregnant or breastfeeding
- Subjects with known or suspected brain metastasis, primary brain tumors, or brain as
the only site of disease
- Exposure to any investigational agent within 4 weeks of study drug administration
- Subjects a history of gastrointestinal disease
We found this trial at
3
sites
Click here to add this to my saved trials
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
Click here to add this to my saved trials